Welcome to Celliaz !
We are looking for passionate and dedicated scientists to grow with Celliaz.

Company Overview
Celliaz is a biopharmaceutical company developing protein and antibody therapeutics that promote retinal regeneration in retina degenerative diseases.

Vision and Mission
Celliaz aims to restore vision based on retinal regeneration in patients with retinal degenerative disease.

Leadership and Management
CEO / Co-Founder

Kyung Hwa Kang,  Ph D.

Dr. Kyung Hwa Kang is CEO and a co-founder of Celliaz. Dr. Kang received a B.S, M.S, and Ph. D. degree in biological sciences from Chung –Ang University and trained as a Postdoctoral fellow at the University of California San Diego (UCSD). She has over 20 years’ experiences in cell and developmental biology. She identified genes that regulate development and degeneration of neurons in Drosophila. She also worked to understand the mechanisms of oncogenesis of neural stem cells in fly brain and screened the chemicals that block the oncogenesis. 
CSO / Co-Founder

Jin Woo Kim,  Ph D.

Dr. Jin Woo Kim is a co-founder and CSO of Celliaz. He received BS, MS, and PhD from KAIST. He also worked as Research Associate in The Salk Institute, La Jolla, USA. Dr. Kim is one of the world-leading scientists in the field of retinal development. He also discovered a phenomenon of intercellular transfer of homeodomain proteins, including Vax1, Otx2, and Prox1, in mouse retina. Dr. Kim’s discoveries on the retinal development and regeneration are the basis of innovative protein and antibody therapeutics of Celliaz.